Eli Lilly terminates license agreement with Rigel over ocadusertib
Summary
Eli Lilly ends Rigel’s ocadusertib agreement, returning the RIPK1 inhibitor rights. Read more here.
Description
Eli Lilly ends Rigel’s ocadusertib agreement, returning the RIPK1 inhibitor rights. Read more here.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source